S. Duran

Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma

R. Bouabdallah, B. Chetaille, D. Blaise, 2014, Hematological oncology.

The use of 'added benefit' to determine the price of new anti-cancer drugs in France, 2004-2017.

P. Viens, J. Mancini, P. Marino, 2021, European journal of cancer.

Efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing haplo-identical hematopoietic SCT

R. Bouabdallah, D. Blaise, C. Oudin, 2013, Bone Marrow Transplantation.

High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation

R. Bouabdallah, D. Blaise, M. Mohty, 2007, Bone Marrow Transplantation.

Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma.

D. Blaise, C. Oudin, C. Chabannon, 2012, Experimental hematology.

Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer.

J. Micallef, Franck Rouby, R. Sabatier, 2018, Journal of geriatric oncology.

Once-weekly liposomal amphotericin B for prophylaxis of invasive fungal infection after graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: a comparative retrospective single-center study.

S. Ranque, B. Esterni, D. Blaise, 2010, Hematology/oncology and stem cell therapy.

De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study

J. Blache, N. Vey, M. Leone, 2013, Intensive Care Medicine.